Welcome to our dedicated page for Kineta news (Ticker: KA), a resource for investors and traders seeking the latest updates and insights on Kineta stock.
Kineta, Inc. (KA) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies. The company's primary asset, KVA12.1, is a VISTA blocking immunotherapy designed to enhance the body's immune response against cancer. Kineta is committed to transforming patients' lives through groundbreaking therapies that target the body's protein homeostasis network.
The proteostasis network is crucial for maintaining the body's natural balance of proteins, protecting against diseases such as Alzheimer's, emphysema, Huntington's disease, and type II diabetes. By developing novel small molecule therapeutics, Kineta aims to control this network, offering potential treatments for various genetic and degenerative disorders.
Kineta's recent achievements include the Phase 1/2 VISTA-101 trial of KVA12.1 in patients with solid cancer tumors, with clinical data announced in March 2024. The company continues to make progress with conference presentations and anticipates future milestones in the first quarter of 2024.
For more information, interested parties can contact:
- Jacques Bouchy, EVP Investor Relations & Business Development: jbouchy@kineta.us
- John Mullaly, LifeSci Advisors, LLC: jmullaly@lifesciadvisors.com
- Bruce Mackle, LifeSci Advisors, LLC: bmackle@lifesciadvisors.com
- General inquiries: info@kineta.us
Rhea-AI Summary
Kineta, Inc. (Nasdaq: KA) to present preclinical data on KVA12123, a VISTA blocking immunotherapy, at the 5th Annual Macrophage-Directed Therapies Summit. The presentation will cover the ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.27%
Tags
-
Rhea-AI Summary
Kineta, Inc. announces positive data from its VISTA-101 clinical trial evaluating KVA12123, the company's VISTA blocking immunotherapy, in patients with advanced solid tumors. The drug demonstrated excellent safety and tolerability, with no dose limiting toxicities observed. It exhibited a greater than dose-proportional pharmacokinetic profile and achieved a greater than 90% VISTA receptor occupancy at the 30 mg dose. Biomarker results showed significant immune responses and anti-tumor effects. Additional data from the trial is expected in Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.74%
Tags
-
Rhea-AI Summary
Kineta, Inc. reports positive safety data from its VISTA-101 clinical trial. They enrolled the first patient for KVA12123 in combination with pembrolizumab. The company expects cash runway into early 2025. Financial highlights show a decrease in cash position and zero revenues for Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.74%
Tags
Rhea-AI Summary
Kineta, Inc. presented new preclinical data on their anti-CD27 agonist monoclonal antibodies at the SITC 38th Annual Meeting. The antibodies demonstrated high binding affinity and specificity, driving strong T cell and NK cell activation. They also showed antitumor efficacy as a single agent and in combination with checkpoint inhibitors in solid and hematological tumor models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.74%
Tags
-
Rhea-AI Summary
Kineta, Inc. announces dosing of first patient in Part B of Phase 1/2 clinical trial for its VISTA blocking immunotherapy, KVA12123, in combination with Merck's KEYTRUDA®
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
-
Rhea-AI Summary
Kineta, Inc. to present new clinical and preclinical data on immuno-oncology therapies at SITC Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
Rhea-AI Summary
Kineta, Inc. to present at Oxford Global Immuno US 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.41%
Tags
-
Rhea-AI Summary
Kineta, Inc. closes registered direct offering, raising approximately $3 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.45%
Tags
-
Rhea-AI Summary
Kineta, Inc. presents new preclinical data on their anti-CD27 agonist monoclonal antibodies (mAbs) for the treatment of advanced solid tumors. The mAb candidates showed high affinity binding and specificity against CD27, with no cross-reactivity detected. They also demonstrated strong agonist properties on T cell proliferation and activation, as well as NK cell activation. The lead mAb candidate showed antitumor efficacy in vivo as a single agent or in combination with other immunotherapies. These findings validate CD27 as an important immuno-oncology target with potential for treating various cancer types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.03%
Tags
News
Rhea-AI Summary
Kineta, Inc. announces purchase and sale agreement for 890,208 shares of common stock in a registered direct offering, expected to raise approximately $3 million for working capital purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.03%
Tags
FAQ
What is the current stock price of Kineta (KA)?
The current stock price of Kineta (KA) is $0.5746 as of September 19, 2024.
What is the market cap of Kineta (KA)?
The market cap of Kineta (KA) is approximately 7.0M.
What does Kineta, Inc. specialize in?
Kineta, Inc. specializes in developing next-generation immunotherapies to treat various diseases, focusing on controlling the body's protein homeostasis network.
What is KVA12.1?
KVA12.1 is Kineta's primary asset, a VISTA blocking immunotherapy designed to enhance the immune response against cancer.
What diseases does Kineta aim to treat?
Kineta aims to treat genetic and degenerative disorders such as Alzheimer's, emphysema, Huntington's disease, and type II diabetes.
What recent achievements has Kineta made?
Kineta's recent achievements include the Phase 1/2 VISTA-101 trial of KVA12.1 in patients with solid cancer tumors, with clinical data announced in March 2024.
How can I contact Kineta, Inc. for more information?
For more information, you can contact Jacques Bouchy at jbouchy@kineta.us, John Mullaly at jmullaly@lifesciadvisors.com, Bruce Mackle at bmackle@lifesciadvisors.com, or send general inquiries to info@kineta.us.
What is the proteostasis network?
The proteostasis network is the body's system for maintaining the natural balance of proteins, protecting against various diseases.
What are proteostasis regulators?
Proteostasis regulators are novel therapies designed to control the proteostasis network and treat diseases related to protein imbalance.
What future milestones does Kineta anticipate?
Kineta anticipates significant milestones in the first quarter of 2024, including advancements in their clinical trials and presentations.
How does Kineta's VISTA blocking immunotherapy work?
Kineta's VISTA blocking immunotherapy, KVA12.1, works by inhibiting the VISTA protein, thereby enhancing the body's immune response against cancer.
Where can I find the latest news about Kineta, Inc.?
The latest news about Kineta, Inc. can be found through their investor relations contact, press releases, and updates on their official website.
Kineta, Inc.
Nasdaq:KA
KA Rankings
KA Stock Data
7.05M
12.26M
34.89%
6%
0.23%
Biotechnology
Pharmaceutical Preparations
United States of America
MERCER ISLAND